Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Purpose of this study is to treat glucocorticoid induced hyperglycemia due to glucocorticoid
pulse therapy in a efficacious, safe and convenient way. Patients with acute exacerbation of
COPD treated with glucocorticoid pulse therapy and at high risk for glucocorticoid induced
hyperglycemia (defined as known type 2 DM or glucose > 10mmol/l at admission) will be
randomized to treatment of dapagliflozin or placebo orally, once daily.
Percentage of time within glucose target range (3,9-10 mmol/l) and incidence rate of
hypoglycemia will be compared between dapagliflozin group and placebo group.